Hooftman Leon's Form 4 filing
Barinthus Biotherapeutics plc. (BRNS) · filed Sep 9, 2026
- Accession no.
- 0001104659-26-106338
- Filed
- Sep 9, 2026, 4:19 PM ET
- Trade date
- Sep 9, 2026
- Filing delay
- Same day
- Rule 10b5-1 plan
- Not checked
This filing lists 2 non-derivative transactions and 2 derivative transactions. It was filed on the trade date.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Hooftman LeonCIK 0002027157 | Officer (Chief Medical Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Sep 9, 2026 | Ordinary Shares | DReturned to the companyDisposed | −195,166 | $0.00 | $0 | 0 | Direct | |
| Sep 9, 2026 | Ordinary Shares | DReturned to the companyDisposed | −140,000 | $0.00 | $0 | 0 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F3
Represents restricted share units ("RSUs") previously granted to the Reporting Person, vesting of which was subject to completion of the transactions contemplated by the Merger Agreement. Each RSU represented the contingent right to receive one Share of the Issuer. At the Effective time, each RSU, whether or not then vested, was automatically released in consideration of the assumption of such RSU by Topco and converted into an RSU relating to the common stock, $0.0001 par value per share, of Topco (the "Topco Common Stock").
Referenced by the price of 2 transactions in Table I.